AstraNu Raises $3.5M to Shrink OCT Imaging
The Bell Labs spin-out will use seed funding led by Celesta Capital to expand its photonics team and prepare for volume manufacturing.
Updated on Nov. 18, 2026 in Healthcare

AstraNu, a 2025 spin-out from Nokia's Bell Labs in New Jersey, raised $3.5 million in seed funding led by Celesta Capital. The company plans to use the capital to expand its photonics development team, validate engine performance, and prepare for volume manufacturing.
Why it matters
AstraNu aims to supply its swept-source OCT imaging engine to established medical device, imaging, and optics companies, with an initial focus on ophthalmology. If its approach works, the company says it could reduce the size and cost of OCT equipment while preserving the sensitivity healthcare applications require.
The $3.5 million seed round is the company's first reported capital raise, and the packaged engine is under one cubic centimeter, more than 10 times smaller than conventional swept-source OCT systems. The company has not disclosed valuation, revenue, or production targets, and its performance claims remain to be validated.
The players
AstraNu
A 2025 spin-out from Nokia's Bell Labs that develops a compact swept-source OCT imaging engine for medical device and optics companies.
Celesta Capital
The venture investment firm that led AstraNu's seed funding round.
New Jersey Innovation Evergreen Fund
A state-supported fund that backed AstraNu's seed round.
The details
The packaged OCT engine uses hybrid integration, combining a planar lightwave circuit photonic chip, integrated balanced photodiodes, a collimating ball lens, and a co-packaged electrothermally actuated MEMS mirror. AstraNu says the design delivers swept-source imaging performance at spectral-domain price points.
Timeline
Shortly before AstraNu was set up, its founders presented their approach at SPIE's BiOS conference in San Francisco.
In 2025, AstraNu spun out from Nokia's Bell Labs research operation in New Jersey.
On November 18, 2026, AstraNu announced its $3.5 million seed funding round.
Market Landscape
AstraNu's spin-out from Bell Labs follows a long pattern of the lab's photonics research being commercialized through startups. Its focus on shrinking OCT hardware places it among companies trying to bring high-end imaging to lower-cost clinical settings.
For patients, a smaller and cheaper OCT engine could eventually mean eye exams with high-resolution imaging in more clinics, but no product from AstraNu is available yet. Clinicians and device buyers should expect any change in equipment cost or availability to depend on partner manufacturers adopting the technology.
The takeaway
Smaller, lower-cost imaging hardware tends to spread first where specialists are scarce, so AstraNu's ophthalmology focus is worth watching for signs of wider clinical adoption.
Further reading
For more on the industry behind this funding, explore Healthcare coverage from across New Jersey.
Source note: This article includes information reported by Optics.






